Genentech reached $1 billion in cooperation to discover new drugs from soil bacteria

Posted on

Genentech reached $1 billion in cooperation to discover new drugs from soil bacteria

May 10, 2018 Source: WuXi PharmaTech

Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];

Today, Lodo Therapeutics, a pharmaceutical development company that identifies and produces bioactive natural products directly from the DNA sequence information of microorganisms in the soil, has announced a strategic drug discovery collaboration with Roche Group member Genentech.

Founded in January 2016, Lodo focuses on creating new therapeutics from nature to reach patients around the world. The company identifies and produces biologically active natural products directly from the DNA sequence information of the microorganisms contained in the soil. The information encoded in the bacterial genome, rather than the accidental discovery in the experiment, prompted the company to discover new drugs. Without being limited by traditional methods of discovering natural product drugs, Lodo has discovered a large number of neglected compounds that can be used for essential processes of life through evolutionary selection and have great potential for treating drug-resistant microbial infections and cancer.

Compounds derived from natural products comprise most small molecule drugs for the treatment of cancer, infections and chronic diseases such as type 2 diabetes. Lodo uses genomic methods, rather than relying on the cultivation of known bacterial strains, to harness the power of microbial evolution to identify novel, natural compounds that have therapeutic potential in the treatment of cancer and resistant bacterial infections. This approach can reduce the time and cost of drug discovery.

Under the terms of the agreement, Genentech will use Lodo's proprietary genomic mining and biosynthetic cluster assembly platform to identify novel molecules with therapeutic potential that target a variety of disease-related targets of interest for Tektronix. Lodo will receive a certain amount of upfront payment and is eligible to receive up to $969 million in R&D and promotion milestone payments based on the achievement of certain scheduled milestones. In addition, Lodo is also eligible for royalties on sales of certain products resulting from this partnership.

â–² Mr. Thong Q. Le, CEO of Lodo and Accelerator Life Science Partners

(Source: Accelerator Life Science Partners official website)

“Lodo Therapeutics' proprietary drug discovery platform is a powerful engine for identifying new compounds with significant therapeutic potential,” said Thong Q. Le, CEO of Lodo and Accelerator Life Science Partners. “We are very excited to work with Genentech. We look forward to demonstrating the power and utility of Lodo's unique technology for the benefit of global human health."

“Only two years after the establishment of Lodo Therapeutics, we were able to strategically collaborate with one of the leaders in the development of innovative drugs, reflecting the potential of our proprietary platform to provide valuable resources to promote its drug discovery program.” Lodo co-founded Dr. David Pompliano, person and chief scientific officer, said.

“We are pleased to work with Genentech to use this innovative platform developed by Lodo to discover new natural products from the soil microbiome,” said Dr. Sean Brady, co-founder of Lodo and associate professor at Rockefeller University.

Dr. James Sabry, senior vice president and global director of Genentech Partnering, commented: "Genentech is committed to acquiring innovative technologies, and we are excited to work with Lodo Therapeutics to use their Metagenomics technology platform to identify difficult drug targets. ”

We look forward to this collaboration to accelerate the development of new drugs and bring the gospel to patients around the world.

Reference materials:

[1] Lodo Therapeutics Corporation Forms Multi-Target Strategic Collaboration with Genentech

[2] Lodo Therapeutics and Genentech Ink Strategic Collaboration Potentially Worth $1 Billion or More

Single Door Safe Box

Fingerprint Safe Box,Residential Safe,Biometric Safe Box,Steel Safe Box

Hebei Yingbo Safe Boxes Co.,Ltd , https://www.ybsafebox.com